title: Low-potassium University of Wisconsin solution for cardioplegia: improved protection of the isolated ischemic neonatal rabbit heart.
abstract: Recovery of cardiac function and high-energy phosphates following ischemia and reperfusion were determined for hearts perfused with low potassium University of Wisconsin solution, high potassium University of Wisconsin solution, St Thomas' solution, or subjected to hypothermia alone. Isolated hearts were arrested for either 3 h at 15 degrees C or 6 h at 20 degrees C (n = 7 for each group) with one of the four solutions and then reperfused. Aortic flow after ischemic arrest at 20 degrees C was 40.3 +/- 13.3%, 79.3 +/- 10.0%, 64.3 +/- 11.9% and 43.9 +/- 15.9% of control values for high potassium University of Wisconsin solution, low potassium University of Wisconsin solution, St Thomas' solution and hypothermia alone, respectively. Similar results were observed in hearts subjected to ischemic arrest at 15 degrees C. Myocardial adenosine triphosphate and creatine phosphate after reperfusion tended to be higher in the low potassium University of Wisconsin solution group. It is concluded that low potassium University of Wisconsin solution may provide reliable cardioplegia during surgery that requires prolonged cardiac arrest in neonates and infants.
authors.affiliation: Second Department of Surgery, Fukui Medical University, Japan. uesaka@fmsrsa.fukui-med.ac.jp
authors.forename: T
authors.initials: T
authors.lastname: Uesaka
authors.forename: Y
authors.initials: Y
authors.lastname: Chiba
authors.forename: A
authors.initials: A
authors.lastname: Ihaya
authors.forename: M
authors.initials: M
authors.lastname: Nara
authors.forename: H
authors.initials: H
authors.lastname: Niwa
authors.forename: R
authors.initials: R
authors.lastname: Muraoka
mesh_terms: D000241:Adenosine / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000378:metabolism; D000493:Allopurinol / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn; D001639:Bicarbonates / Q000494:pharmacology; D002122:Calcium Chloride / Q000494:pharmacology; D002314:Cardioplegic Solutions / Q000494:pharmacology*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005978:Glutathione / Q000494:pharmacology; D006321:Heart / Q000187:drug effects*; D006323:Heart Arrest / Q000378:metabolism / Q000517:prevention & control*; D006324:Heart Arrest, Induced / Q000379:methods*; D006439:Hemodynamics / Q000187:drug effects; D007036:Hypothermia, Induced; D066298:In Vitro Techniques; D007328:Insulin / Q000494:pharmacology; D008274:Magnesium / Q000494:pharmacology; D019188:Organ Preservation Solutions; D010725:Phosphocreatine / Q000378:metabolism; D011188:Potassium / Q000008:administration & dosage*; D011189:Potassium Chloride / Q000494:pharmacology; D011817:Rabbits; D011887:Raffinose / Q000494:pharmacology; D012965:Sodium Chloride / Q000494:pharmacology
chemical_list: D001639:Bicarbonates; D002314:Cardioplegic Solutions; D007328:Insulin; D019188:Organ Preservation Solutions; C041711:St. Thomas' Hospital cardioplegic solution; C055206:University of Wisconsin-lactobionate solution; D010725:Phosphocreatine; D012965:Sodium Chloride; D000493:Allopurinol; D011189:Potassium Chloride; D000255:Adenosine Triphosphate; D005978:Glutathione; D008274:Magnesium; D000241:Adenosine; D002122:Calcium Chloride; D011887:Raffinose; D011188:Potassium